

Barbara K. Rimer, DrPH
Chair, President's Cancer Panel



Update for the National Cancer Advisory Board

September 7, 2016



Mission

The Panel shall monitor the development and execution of the activities of the National Cancer Program, and shall report directly to the President.

Any delays or blockages in the rapid execution of the Program shall immediately be brought to the attention of the President.



Members

Barbara K. Rimer, DrPH

Univ. of North Carolina at Chapel Hill



Hill Harper, JD

Cancer Survivor, Actor, and Best-Selling Author



Owen N. Witte, MD

University of California Los Angeles





Overview

2012-2013 Report to the President

Accelerating HPV Vaccine Uptake: Urgency for Action to Prevent Cancer

Upcoming Report to the President

*Improving Cancer-Related Outcomes with Connected Health**

2016-2017 Series

Ensuring Patients' Access to High-Value Cancer Drugs

*Still in draft



2012-2013 Report to the President

Accelerating HPV Vaccine Uptake: Urgency for Action to Prevent Cancer



HPV Vaccines **Prevent Cancers.**
Why Are **So Few** U.S. Adolescents Vaccinated?



A Report to the President of the United States
from
The President's Cancer Panel

President's Cancer Panel Annual Report 2012-2013

ACCELERATING HPV VACCINE UPTAKE: URGENCY FOR ACTION TO PREVENT CANCER

Share:

Human papillomaviruses (HPV) cause most cases of cervical cancer and large proportions of vaginal, vulvar, anal, penile, and oropharyngeal cancers. HPV also causes genital warts and recurrent respiratory papillomatosis. HPV vaccines could dramatically reduce the incidence of HPV-associated cancers and other conditions among both females and males, but uptake of the vaccines has fallen short of target levels. The President's Cancer Panel finds underuse of HPV vaccines a serious but correctable threat to progress against cancer. In this report, the Panel presents four goals to increase HPV vaccine uptake: three of these focus on the United States and the fourth addresses ways the United States can help to increase global uptake of the vaccines. Several high-priority research questions related to HPV and HPV vaccines also are identified.


- Letter to President Obama
- Executive Summary
- Recommendations at a Glance
- Download Full Report (PDF)

Click below to read more.

HOW TO ACCELERATE HPV VACCINE UPTAKE IN THE U.S.



➔ Reduce Missed Clinical Opportunities to Recommend and Administer Vaccines



➔ Increase Parents', Caregivers', and Adolescents' Acceptance of HPV Vaccines



➔ Maximize Access to HPV Vaccination Services

INCREASE GLOBAL HPV VACCINATION

CONDUCT HIGH-PRIORITY RESEARCH



Continued Impact of 2012-2013 HPV Report*

- ❑ NCQA Updated Quality Measures for HEDIS 2017: HPV vaccination for both males & females will be reported in a single measure, along with other adolescent vaccines (meningococcal and Tdap).
- ❑ 69 NCI-Designated Cancer Centers released statement urging greater uptake of HPV vaccination for cancer prevention.
- ❑ HPV Summit gathered NCI Cancer Centers, NCI, CDC, & ACS on June 30.



* Of course, none of these activities are due to the report alone.



Continued Impact of 2012-2013 HPV Report

- ❑ ASCO released statement urging aggressive efforts to increase HPV vaccination to prevent HPV-related cancers.
- ❑ National HPV Vaccination Roundtable 2016 meeting was held August 30-31, 2016.
- ❑ Advisory Committee on Immunization Practices is reviewing evidence for 2-dose schedule with 9-valent HPV vaccine.



2014-2015 Series

Improving Cancer-Related Outcomes with Connected Health



Series Co-Chairs



David K. Ahern, PhD

- Director, Program in Behavioral Informatics and eHealth, Brigham and Women's Hospital
- Special Advisor, Division of Cancer Control and Population Sciences, National Cancer Institute



Bradford W. Hesse, PhD

- Chief, Health Communication and Informatics Research Branch, Division of Cancer Control and Population Sciences, National Cancer Institute



Connected Health Report Progress



- ❑ Content is being finalized.
- ❑ External review by multiple partners, including:
 - Office of the National Coordinator for Health Information Technology (ONC)
 - American Society of Clinical Oncology (ASCO)
 - Federal Communications Commission (FCC)
 - National Cancer Institute (NCI)
 - Centers for Disease Control and Prevention (CDC)
 - Other content experts
- ❑ Draft was sent to White House Liaison; excellent feedback received.
- ❑ Report will be released later this fall.




Connected Health Report Progress

Panel will make recommendations on topic areas important to connected health and cancer, including:

- Enabling development of tools to support individuals' health management and providers' provision of care;
- Encouraging health information flow between health institutions, patients, and their caregivers; &
- Strengthening health IT infrastructure.

Encouraging information flow between people and institutions





2016-2017 Series

Ensuring Patients' Access to High-Value Cancer Drugs





Workshop #1: Access to and Cost of Cancer Drugs in a Changing Healthcare Landscape

*New York, NY
June 10, 2016*



- ❑ Innovations in cancer therapy can transform treatment.
- ❑ Accessing needed drugs is increasingly difficult for some patients.
- ❑ Drug costs & access are creating challenges for patients, providers, healthcare systems, & payers.
- ❑ Panel will examine: factors influencing drug cost and pricing, use of rational pricing models, rising prices of cancer therapies (esp. combination therapies), & streamlining clinical development processes.



Participants

Gary Gilliland, MD, PhD (Series Co-Chair)

- President and Director, Fred Hutchinson Cancer Research Center

Ann Geiger, PhD, MPH (DCCPS Liaison)

- Associate Director (Acting), Healthcare Delivery Research Program, DCCPS, NCI

Other sectors represented

- Oncologists and oncology organizations (ASCO); potentially, other providers
- Patients and patient advocacy organizations
- Pharmaceutical and biotechnology companies
- Health economists
- Academic researchers
- Payers
- Federal agencies (FDA, CMS, NIH/NCI)



Workshop #2: Emerging Opportunities to Streamline Cancer Drug Development

*Arlington, VA
December 09, 2016*



- ❑ Panel will convene thought leaders from industry, academic institutions, foundations, government, & advocacy.
- ❑ Agenda planning underway
- ❑ Panel's goal is to identify key actions that could:
 - Streamline drug development & approval process.
 - Lower research & development costs.
 - Ensure patients' access to high-value cancer drugs.



Upcoming Workshops

□ Workshop #3: Rational Pricing Models (March, 2017)

Key topics:

- Value-based frameworks and their influence on pricing
- Establishing pricing and coverage transparency
- Supporting competition among drug makers

□ Workshop #4: Rational Payment Models (Summer, 2017)

Key topics:

- Identifying needed changes to existing payment models
- Developing outcome- and indication-based new payment models
- Establishing policies for how much patients should expect to pay out-of-pocket



Contact Us

President's Cancer Panel

9000 Rockville Pike

Bld. 31/B2B37

Bethesda, MD 20892

(301) 451-9399

PresCancerPanel@mail.nih.gov

<http://PresCancerPanel.cancer.gov>

@PresCancerPanel on Twitter